Drug intelligence / Profile preview

bifidobacterium bifidum CCFM1192

Development stage: Unknown
Lead developer: Tinghu District People's Hospital
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium bifidum CCFM1192 is a specific probiotic strain currently under investigation for its therapeutic potential in treating respiratory allergies in infants. It is being studied in a randomized, double-blind, controlled clinical trial to understand its effects and underlying mechanisms. As a *Bifidobacterium* strain, it is a type of "good" bacteria commonly found in the human gut, particularly in breastfed infants, and is known to produce lactic and acetic acid, contributing to gut health. It is considered a nutraceutical and a live biotherapeutic product.

Other names: 婴儿双歧杆菌CFM1192

Beyond the preview

Go deeper on bifidobacterium bifidum CCFM1192.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium bifidum CCFM1192.

Explore the full profile